Cytotoxic agents comprising new tomaymycin derivatives

1. A compound of formula (I)

wherein

represents an optional single bond;

represents either a single bond or a double bond;

provided that when represents a single bond, U and U′, the same or different, independently represent H, and W and W′, the same or different, are independently selected from the group consisting of —OH, —OR, —OCOR, —OCOOR, —OCONRR′, —NRCONRR′, —OCSNHR, —SH, —SR, —SOR, —SOOR, —SO 3 , —OSO 3 , —NRSOOR, N 3 , a cyano, a halo, a trialkyl and triarylphosphonium;

and when represents a double bond, U and U′ are absent and W and W′ represent H;

R1, R2, R1′, R2′ are the same or different and independently chosen from halide and alkyl optionally substituted by one or more Hal, CN, NRR′, CF 3 , OR, Aryl, Het, S(O) q R; or R 1 and R 2 and R 1 ′ and R 2 ′ form together a double bond containing group ═B and ═B′ respectively;

B and B′ are the same or different and independently represent alkenyl being optionally substituted by one or more Hal, CN, R, CF 3 , OR, Aryl, HetS(O) q R; or B and B′ represent an oxygen atom;

X and X′ are the same or different and independently chosen from one or more —O—, —NR—, —(C═O)—, and —S(O) q —;

A and A′ are the same or different and independently represent alkyl or alkenyl optionally containing an oxygen, a nitrogen or a sulfur atom and each being optionally substituted by one or more Hal, CN, NRR′, CF 3 , OR, S(O) q R, Aryl, Het, Alkyl, or Alkenyl;

Y and Y′ are the same or different and independently chosen from H and OR;

T is —NR—, or a 4 to 10-membered aryl, cycloalkyl, heterocyclic or heteroaryl, each being optionally substituted by one or more Hal, CN, NRR′, CF 3 , R, OR, S(O) q R, or alkyl, and substituted by one more linkers of formula:

-G-D-(Z) p -S-Z′

wherein

G is a single or double bond, —O—, —S—or —NR—;

D is a single bond or -E-, -E-NR—, -E-NR—F—, -E-O—, -E-O—F—, -E-NR—CO—, -E-NR—CO—F—, -E-CO—, —CO-E-, -E-CO—F, -E-S—, -E-S—F—, -E-NR—C—S—, -E-NR—CS—F—;

where E and F are the same or different and are independently chosen from linear or branched —(OCH 2 CH 2 ) i Alkyl(OCH 2 CH 2 ) j —, -Alkyl(OCH 2 CH 2 ) i -Alkyl-, —(OCH 2 CH 2 ) i —, —(OCH 2 CH 2 ) i Cycloalkyl(OCH 2 CH 2 ) j —, —(OCH 2 CH 2 ) i Heterocyclic(OCH 2 CH 2 ) j —, —(OCH 2 CH 2 ) i Aryl(OCH 2 CH 2 ) j —, —(OCH 2 CH 2 ) i Heteroaryl(OCH 2 CH 2 ) j —, -Alkyl-(OCH 2 CH 2 ) i Alkyl(OCH 2 CH 2 ) j —, -Alkyl-(OCH 2 CH 2 ) i —, -Alkyl-(OCH 2 CH 2 ) j Cycloalkyl(OCH 2 CH 2 ) j —, -Alkyl(OCH 2 CH 2 ) i Heterocyclic(OCH 2 CH 2 ) j —, -Alkyl-(OCH 2 CH 2 ) i Aryl(OCH 2 CH 2 ) j —, -Alkyl(OCH 2 CH 2) i Heteroaryl(OCH 2 CH 2 ) j —, -Cycloalkyl-Alkyl-, -Alkyl-Cycloalkyl-, -Heterocyclic-Alkyl-, -Alkyl-Heterocyclic-, -Alkyl-Aryl-, -Aryl-Alkyl-, -Alkyl-Heteroaryl-, -Heteroaryl-Alkyl-;

i and j, identical or different, are integers and independently chosen from 0, 1 to 2000;

Z is linear or branched -Alkyl-;

p is 0 or 1; and

Z′ represents H, a thiol protecting group COR, R 20 or SR 20 , wherein R 20 represents H, methyl, Alkyl, optionally substituted Cycloalkyl, aryl, heteroaryl or heterocyclic;

n, n′, equal or different are 0 or 1;

q is 0, 1 or 2;

R and R′ are equal or different and independently chosen from H, Alkyl, Aryl, each being optionally substituted by Hal, CN, NRR′, CF 3 , R, OR, S(O) q R, Aryl, or Het; or pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 , wherein n=n′=1.

3. A compound according to claim 1 of formula (II)

wherein:

W and W′, the same or different, are independently selected from the group consisting of OH, —OR, —OCOR, —OCOOR, —OCONRR′, —NRCONRR′, —OCSNHR, —SH, —SR, —SOR, —SOOR, —SO 3 —OSO 3 , —NRSOOR, N 3 , a cyano, a halo, a trialkyl and triarylphosphonium; or

a pharmaceutically acceptable salt of such compound thereof.

4. A compound according to claim 2 of formula (II)

wherein:

W and W′, the same or different, are independently selected from the group consisting of OH, —OR, —OCOR, —OCOOR, —OCONRR′, —NRCONRR′, —OCSNHR, —SH, —SR, —SOR, —SOOR, —SO 3 − , —NRSOOR, a cyano, a halo, a trialkyl and triarylphosphonium; or

a pharmaceutically acceptable salt thereof.

5. A compound according to claim 1 of the formula

a pharmaceutically acceptable salt thereof.

6. A compound according to claim 1 of the formula:

or

a pharmaceutically acceptable salt.

7. A compound according to claim 1 wherein X=X′; or a pharmaceutically acceptable salt thereof.

8. A compound according to claim 7 , wherein X=X′=O; or a pharmaceutically acceptable salt thereof.

9. A compound according to claim 1 wherein A=A′; or a pharmaceutically acceptable salt thereof.

10. A compound according to claim 9 wherein A=A′=linear unsubstituted alkyl; or a pharmaceutically acceptable salt thereof.

11. A compound according to claim 1 wherein Y=Y′; or a pharmaceutically acceptable salt thereof.

12. A compound according to claim 11 , wherein Y=Y′=Oalkyl; or a pharmaceutically acceptable salt thereof.

13. A compound according to claim 1 wherein T is a phenyl or pyridyl, each being optionally substituted by one or more Hal, CN, NRR′, CF 3 , R, OR, S(O) q R; or a pharmaceutically acceptable salt thereof.

14. A compound according to claim 2 wherein T is a phenyl or pyridyl, each being optionally substituted by one or more Hal, CN, NRR′, CF 3 , R, OR, S(O) q R; or pharmaceutically acceptable salt.

15. A compound according to claim 1 , wherein G is a single bond or —O— or —NR—; or pharmaceutically acceptable salt thereof.

16. A compound according to claim 15 , wherein G is —O—; or a pharmaceutically acceptable salt thereof.

17. A compound according to claim 1 , wherein D is a single bond or -E-, -E-NR—, -E-CO—, —CO-E-, or -E-NR—CO—; or a pharmaceutically acceptable salt thereof.

18. A compound according to claim 1 , wherein D is -E-NR—CO—; or a pharmaceutically acceptable salt thereof.

19. A compound according to claim 1 , wherein E is a linear or branched -Alkyl-, —(OCH 2 CH 2 ) i — or -Alkyl-heterocyclic; or a pharmaceutically acceptable salt thereof.

20. A compound according to claim 1 , wherein Z is —(CH 2 ) 2 —C(CH 3 ) 2 —; or a pharmaceutically acceptable salt thereof.

21. A compound according to claim 1 , wherein p is 1; or a pharmaceutically acceptable salt thereof.

22. A compound according to claim 1 , wherein Z′ is H or SR 20 , wherein R 20 represents Alkyl, aryl, heterocyclic or heteroaryl; or a pharmaceutically acceptable salt thereof.

23. A compound of formula (I)

wherein

represents an optional single bond;

represents either a single bond or a double bond;

provided that when represents a single bond, U and U′, the same or different, independently represent H, and W and W′, the same or different, are independently selected from the group consisting of —OH, —OR, —OCOR, —OCOOR, —OCONRR′, —NRCONRR′, —OCSNHR, —SH, —SR, —SOR, —SOOR, —SO 3 , —OSO 3 , —NRSOOR, N 3 , a cyano, a halo, a trialkyl and triarylphosphonium;

and when represents a double bond, U and U′ are absent and W and W′ represent H;

R1, R2, R1′, R2′ are the same or different and independently chosen from halide and alkyl optionally substituted by one or more Hal, CN, NRR′, CF 3 , OR, Aryl, Het, S(O) q R; or R 1 and R 2 and R 1 ′ and R 2 ′ form together a double bond containing group ═B and ═B′ respectively;

B and B′ are the same or different and independently represent alkenyl being optionally substituted by one or more Hal, CN, R, CF 3 , OR, Aryl, HetS(O) q R; or B and B′ represent an oxygen atom;

X and X′ are the same or different and independently chosen from one or more —O—, —NR—, —(C═O)—, and —S(O) q —;

A and A′ are the same or different and independently represent alkyl or alkenyl optionally containing an oxygen, a nitrogen or a sulfur atom and each being optionally substituted by one or more Hal, CN, NRR′, CF 3 , OR, S(O) q R, Aryl, Het, Alkyl, or Alkenyl;

Y and Y′ are the same or different and independently chosen from H and OR;

T is —NR—, or a 4 to 10-membered aryl, cycloalkyl, heterocyclic or heteroaryl, each being optionally substituted by one or more Hal, CN, NRR′, CF 3 , R, OR, S(O) q R, or alkyl, and substituted by one more linkers;

n, n′, equal or different are 0 or 1;

q is 0, 1 or 2;

R and R′ are equal or different and independently chosen from H, Alkyl, Aryl, each being optionally substituted by Hal, CN, NRR′, CF 3 , R, OR, S(O) q R, Aryl, or Het;

wherein said one or more linkers is chosen from:

—(CR 13 R 14 ) t (CR 15 R 16 ) u (OCH 2 CH 2 ) y SZ′, —(CR 13 R 14 ) t (CR 17 ═CR 18 )(CR 15 R 16 ) y (OCH 2 CH 2 ) y SZ′, —(CR 13 R 14 ) t (NR 19 CO)(CR 15 R 16 ) u (OCH 2 CH 2 ) y SZ′, —(CR 13 R 14 ) t (OCO)(R 15 R 16 ) u (OCH 2 CH 2 ) y SZ′, —(CR 13 R 14 ) t (CO)(CR 15 R 16 ) u (OCH 2 CH 2 ) y SZ′, —(CR 13 R 14 ) t (CONR 19 )(CR 15 R 16 ) u (OCH 2 CH 2 ) y SZ′, —(CR 13 R 14 ) t -phenyl-CO(CR 15 R 16 ) u SZ′, —(CR 13 R 14 ) t -furyl-CO(CR 15 R 16 ) u SZ′, —(CR 13 R 14 ) t -oxazolyl-CO(CR 15 R 16 ) u SZ′,—(CR 13 R 14 ) t -thiazolyl-CO(CR 15 R 16 ) u SZ′, —(CR 13 R 14 ) t -thienyl-CO(CR 15 R 16 ) u SZ′, —(CR 13 R 14 ) t -imidazolyl-CO(CR 15 R 16 ) u SZ′, —(CR 13 R 14 ) t -morpholino-CO(CR 15 R 16 ) u SZ′, —(CR 13 R 14 ) t -piperazino-CO(CR 15 R 16 ) u SZ′, —(CR 13 R 14 ) t -N-methyl-piperazino-CO(CR 15 R 16 ) u SZ′,

—(CR 13 R 14 ) t -phenyl-QSZ′, —(CR 13 R 14 ) t -furyl-QSZ′, —(CR 13 R 14 ) t -oxazolyl-QSZ′, —(CR 13 R 14 ) t -thiazolyl-QSZ′, —(CR 13 R 14 ) t -thienyl-QSZ′, —(CR 13 R 14 ) t -imidazolyl-QSZ′, —(CR 13 R 14 ) t -morpholino-QSZ′, —(CR 13 R 14 ) t -piperazino-QSZ′, —(CR 13 R 14 ) t -N-methylpiperazino-QSZ′, or

—O(CR 13 R 14 ) t (CR 15 R 16 ) u (OCH 2 CH 2 ) y SZ′, —O(CR 13 R 14 ) t (NR 19 CO)(CR 15 R 16 ) u (OCH 2 CH 2 ) y SZ′, —O(CR 13 R 14 ) t (CR 17 ═CR 18 )(CR 15 R 16 ) t (OCH 2 CH 2 ) y SZ′, —O-phenyl-QSZ′, —O-furyl-QSZ′, —O-oxazolyl-QSZ′, —O-thiazolyl-QSZ′, —O-thienyl-QSZ′, —O-imidazolyl-QSZ′, —O-morpholino-QSZ′, —O-piperazino-QSZ′, —O-N-methylpiperazino-QSZ′,

—OCO—(CR 13 R 14 ) t (CR 17 ═CR 18 )(CR 15 R 16 ) u (OCH 2 CH 2 ) y SZ′, —OCONR 12 (CR 13 R 14 ) t (CR 15 R 16 ) u (OCH 2 CH 2 ) y SZ′, —OCO-phenyl-QSZ′, —OCO-furyl-QSZ′, —OCO-oxazolyl-QSZ′, —OCO-thiazolyl-QSZ′, —OCO-thienyl-QSZ′, —OCO-imidazolyl-QSZ′, —OCO-morpholino-QSZ′, —OCO-piperazino-QSZ′, —OCO—N-methylpiperazino-QSZ′, or

—CO(CR 13 R 14 ) t (CR 15 R 16 ) u (OCH 2 CH 2 ) y SZ′, —CO—(CR 13 R 14 ) t (CR 17 ═CR 18 )(CR 15 R 16 ) u (OCH 2 CH 2 ) y SZ′, —CONR 12 (CR 13 R 14 ) t (CR 15 R 16 ) u (OCH 2 CH 2 ) y SZ′, —CO-phenyl-QSZ′, —CO-furyl-QSZ′, —CO-oxazolyl-QSZ′, —CO-thiazolyl-QSZ′, —CO-thienyl-QSZ′, —CO-imidazolyl-QSZ′, —CO-morpholino-QSZ′, —CO-piperazino-QSZ′, —CO-piperidino-QSZ′, —CO—N-methylpiperazino-QSZ′,

—NR 19 (CR 13 R 14 ) t (CR 15 R 16 ) u (OCH 2 CH 2 ) y SZ′, —NR 19 CO(CR 13 R 14 ) t (CR 15 R 16 ) u (OCH 2 CH 2 ) y SZ′, —NR 19 (CR 13 R 14 ) t (CR 17 ═CR 18 )(CR 15 R 16 ) t (OCH 2 CH 2 ) y SZ′, —NR 19 CO(CR 13 R 14 ) t (CR 17 ═CR 18 )(CR 15 R 16 ) t (OCH 2 CH 2 ) y SZ′, —NR 19 CONR 12 (CR 13 R 14 ) t (CR 15 R 16 ) u (OCH 2 CH 2 ) y SZ′, —NR 19 CO NR 12 (CR 13 R 14 ) t (CR 17 ═CR 18 )(CR 15 R 16 ) t (OCH 2 CH 2 ) y SZ′, —NR 19 CO-phenyl-QSZ′, —NR 19 CO-furyl-QSZ′, —NR 19 CO-oxazolyl-QSZ′, —NR 19 CO-thiazolyl-QSZ′, —NR 19 CO-thienyl-QSZ′, —NR 19 CO-imidazolyl-QSZ′, —NR 19 CO-morpholino-QSZ′, —NR 19 CO-piperazino-QSZ′, —NR 19 CO-piperidino-QSZ′, —NR 19 CO—N-methylpiperazino-QSZ′, —NR 19 -phenyl-QSZ′, —NR 19 -furyl-QSZ′, —NR 19 -oxazolyl-QSZ′, —NR 19 -thiazolyl-QSZ′, —NR 19 -thienyl-QSZ′, —NR 19 -imidazolyl-QSZ′, —NR 19 -morpholino-QSZ′, —NR 19 -piperazino-QSZ′, —NR 19 -piperidino-QSZ′, —NR 19 —N-methylpiperazino-QSZ′, —NR 19 CO—NR 12 -phenyl-QSZ′, —NR 19 CO—NR 12 -oxazolyl-QSZ′, —NR 19 CO—NR 12 -thiazolyl-QSZ′, —NR 19 CO—NR 12 -thienyl-QSZ′, —NR 19 CO—NR 12 -piperidino-QSZ′,

—S(O) q (CR 13 R 14 ) t (CR 15 R 16 ) u (OCH 2 CH 2 ) y SZ′, —S(O) q (CR 13 R 14 ) t (CR 17 ═CR 18 )(CR 15 R 16 ) t (OCH 2 CH 2) y SZ′,

—SCONR 12 (CR 13 R 14 ) t (CR 15 R 16 ) u (OCH 2 CH 2 ) y SZ′,

—SCO-morpholino-QSZ′, —SCO-piperazino-QSZ′, —SCO-piperidino-QSZ′, and —SCO—N-methylpiperazino-QSZ′, wherein:

Z′ is H, a thiol protective group, R 20 ′ or SR 20 ′ wherein R 20 ′ represents alkyl, aryl, heterocyclic or heteroaryl,

wherein Q is a direct link or a linear alkyl or branched alkyl having from 1-10 carbon atoms or a polyethylene glycol spacer with 2 to 20 repeating ethylene oxy units;

R 19 and R 12 are the same or different and are linear alkyl, branched alkyl or cyclic alkyl having from 1 to 10 carbon atoms, or simple or substituted aryl or heterocyclic, and R 12 can in addition be H,

R 13 , R 14 , R 15 and R 16 are the same or different and are H or a linear or branched alkyl having from 1 to 4 carbon atoms,

R 17 and R 18 are H or alkyl,

u is an integer from 1 to 10 and can also be 0,

t is an integer from 1 to 10 and can also be 0,

y is an integer from 1 to 20 and can also be 0; or

a pharmaceutically acceptable salt thereof.

24. A compound according to claim 1 which is:

8,8′-[1,3-benzenediylbis(methyleneoxy)]-bis[(S)-2-eth-(E)-ylidene-7-methoxy-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one]

8,8′-[5-methoxy-1,3-benzenediylbis(methyleneoxy)]-bis[(S)-2-eth-(E)-ylidene-7-methoxy-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one]

8,8′-[1,5-pentanediylbis(oxy)]-bis[(S)-2-eth-(E)-ylidene-7-methoxy-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one]

8,8′-[1,4-butanediylbis(oxy)]-bis[(S)-2-eth-(E)-ylidene-7-methoxy-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one]

8,8′-[3-methyl-1,5-pentanediylbis(oxy)]-bis[(S)-2-eth-(E)-ylidene-7-methoxy-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one]

8,8′-[2,6-pyridinediylbis(oxy)]-bis[(S)-2-eth-(E)-ylidene-7-methoxy-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one]

8,8′-[4-(3-tert-butoxycarbonylaminopropyloxy)-2,6-pyridinediylbis-(methyleneoxy)]-bis[(S)-2-eth-(E)-ylidene-7-methoxy-1,2,3,11a-tetrahydro-5H-pyrrolo [2,1-c][1,4]benzodiazepin-5-one]

8,8′-[5-(3-aminopropyloxy)-1,3-benzenediylbis(methyleneoxy)]-bis[(S)-2-eth-(E)-ylidene-7-methoxy-1,2,3,11a-tetrahydro-5H-pyrrolo [2,1-c][1,4]benzodiazepin-5-one]

8,8′-[5-(N-methyl-3-tert-butoxycarbonylaminopropyl)-1,3-benzenediylbis-(methyleneoxy)]-bis[(S)-2-eth-(E)-ylidene-7-methoxy-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one]

8,8′-{5-[3-(4-methyl-4-methyldisulfanyl-pentanoylamino)propyloxy]-1,3-benzenediylbis(methyleneoxy)}-bis[(S)-2-eth-(E)-ylidene-7-methoxy-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one]

8,8′-[5-acetylthiomethyl-1,3-benzenediylbis(methyleneoxy)]-bis[(S)-2-methylene-7-methoxy-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one]bis-{2-[(S)-2-methylene-7-methoxy-5-oxo-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yloxy]-ethyl}-carbamic acid tert-butyl ester

8,8′-[3-(2-acetylthioethyl)-1,5-pentanediylbis(oxy)]-bis[(S)-2-methylene-7-methoxy-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one]

8,8′-[5-(N-4-mercapto-4,4-dimethylbutanoyl)amino-1,3-benzenediylbis(methyleneoxy)]-bis[7-methoxy-2-methylene-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one]

8,8′-[5-(N-4-methyldithio-4,4-dimethylbutanoyl)-amino-1,3-benzenediylbis(methyleneoxy)]-bis[7-methoxy-2-methylene-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one]

8,8′-[5-(N-methyl-N-(2-mercapto-2,2-dimethylethyl)amino-1,3-benzenediyl(methyleneoxy)]-bis[7-methoxy-2-methylene-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one]

8,8′-[5-(N-methyl-N-(2-methyldithio-2,2-dimethylethyl)amino-1,3-benzenediyl(methyleneoxy)]-bis[7-methoxy-2-methylene-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one]

8,8′-[(4-(2-(4-mercapto-4-methyl)-pentanamido-ethoxy)-pyridin-2,6-dimethyl)-dioxy]-bis[(S)-2-eth-(E)-ylidene-7-dimethoxy-1,2,3,11a-tetrahydro-pyrrolo[2,1-c][1,4]benzodiazepin-5-one]

8,8′-[(1-(2-(4-methyl-4-methyldisulfanyl)-pentanamido-ethoxy)-benzene-3,5-dimethyl)-dioxy]-bis[(S)-2-eth-(E)-ylidene-7-dimethoxy-1,2,3,11a-tetrahydro-pyrrolo[2,1-c][1,4]benzodiazepin-5-one]

8,8′-[(4-(3-(4-methyl-4-methyldisulfanyl)-pentanamido-propoxy)-pyridin-2,6-dimethyl)-dioxy]-bis[(S)-2-eth-(E)-ylidene-7-dimethoxy-1,2,3,11a-tetrahydro-pyrrolo[2,1-c][1,4]benzodiazepin-5-one]

8,8′-[(4-(4-(4-methyl-4-methyldisulfanyl)-pentanamido-butoxy)-pyridin-2,6-dimethyl)-dioxy]-bis[(S)-2-eth-(E)-ylidene-7-dimethoxy-1,2,3,11a-tetrahydro-pyrrolo[2,1-c][1,4]benzodiazepin-5-one]

8,8′-[(4-(3[4-(4-methyl-4-methyldisulfanyl-pentanoyl)-piperazin-1-yl]-propyl)-pyridin-2,6-dimethyl)-dioxy]-bis[(S)-2-eth-(E)-ylidene-7-dimethoxy-1,2,3,11a-tetrahydro-pyrrolo[2,1-c][1,4]benzodiazepin-5-one]

8,8′-[(1-(3-[4-(4-methyl-4-methyldisulfanyl-pentanoyl)-piperazin-1-yl]-propyl)-benzene-3,5-dimethyl)-dioxy]-bis[(S)-2-eth-(E)-ylidene-7-dimethoxy-1,2,3,11a-tetrahydro-pyrrolo[2,1-c][1,4]benzodiazepin-5-one]

8,8′-[(4-(2-{2-[2-(4-methyl-4-methyldisulfanyl-pentanoylamino)-ethoxy]-ethoxy}-ethoxy)-pyridin-2,6-dimethyl)-dioxy]-bis[(S)-2-eth-(E)-ylidene-7-dimethoxy-1,2,3,11a-tetrahydro-pyrrolo[2,1-c][1,4]benzodiazepin-5-one]

8,8′-[(1-(2-{2-[2-(2-{2-[2-(4-methyl-4-methyldisulfanyl-pentanoylamino)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-benzene-3,5-dimethyl)-dioxy]-bis[(S)-2-eth-(E)-ylidene-7-dimethoxy-1,2,3,11a-tetrahydro-pyrrolo [2,1-c][1,4]benzodiazepin-5-one]

8,8′-[(1-(2-{2-[2-(4-methyl-4-methyldisulfanyl-pentanoylamino)-ethoxy]-ethoxy}-ethoxy)-benzene-3,5-dimethyl)-dioxy]-bis[(S)-2-eth-(E)-ylidene-7-dimethoxy-1,2,3,11a-tetrahydro-pyrrolo[2,1-c][1,4]benzodiazepin-5-one]

8,8′-[(4-(2-{2-[2-(2-{2-[2-(4-methyl-4-methyldisulfanyl-pentanoylamino)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-pyridin-2,6-dimethyl)-dioxy]-bis[(S)-2-eth-(E)-ylidene-7-dimethoxy-1,2,3,11a-tetrahydro-pyrrolo[2,1-c][1,4]benzodiazepin-5-one]

8,8′-[(1-(2-[methyl-(2-methyl-2-methyldisulfanyl-propyl)-amino]-ethoxy)-benzene-3,5-dimethyl)-dioxy]-bis[(S)-2-eth-(E)-ylidene-7-dimethoxy-1,2,3,11a-tetrahydro-pyrrolo[2,1-c][1,4]benzodiazepin-5-one]

8,8′-[(4-(3-[methyl-(4-methyl-4-methyldisulfanyl-pentanoyl)-amino]-propyl)-pyridin-2,6-dimethyl)-dioxy]-bis[(S)-2-eth-(E)-ylidene-7-dimethoxy-1,2,3,11a-tetrahydro-pyrrolo[2,1-c][1,4]benzodiazepin-5-one]

8,8′-[(4-(3-[methyl-(2-methyl-2-methyldisulfanyl-propyl)-amino]-propyl)-pyridin-2,6-dimethyl)-dioxy]-bis[(S)-2-eth-(E)-ylidene-7-dimethoxy-1,2,3,11a-tetrahydro-pyrrolo[2,1-c][1,4]benzodiazepin-5-one] or

8,8′-[(1-(4-methyl-4-methyldisulfanyl)-pentanamido)-benzene-3,5-dimethyl)-dioxy]-bis[(S)-2-eth-(E)-ylidene-7-dimethoxy-1,2,3,11a-tetrahydro-pyrrolo[2,1-c][1,4]benzodiazepin-5-one]; or

the corresponding mercapto compound thereof; or a pharmaceutically acceptable salt thereof.